Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Down 14.8% in December

Aprea Therapeutics, Inc. (NASDAQ:APRE) was the target of a large decrease in short interest during the month of December. As of December 31st, there was short interest totalling 10,900 shares, a decrease of 14.8% from the December 15th total of 12,800 shares. Approximately 0.2% of the company’s stock are sold short. Based on an average trading volume of 28,500 shares, the days-to-cover ratio is currently 0.4 days.

Insider Activity

In other news, Director Marc Duey sold 6,462 shares of the company’s stock in a transaction on Friday, October 18th. The shares were sold at an average price of $4.58, for a total value of $29,595.96. Following the completion of the transaction, the director now owns 233,651 shares in the company, valued at approximately $1,070,121.58. This represents a 2.69 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 12.80% of the company’s stock.

Institutional Investors Weigh In On Aprea Therapeutics

An institutional investor recently bought a new position in Aprea Therapeutics stock. Stonepine Capital Management LLC acquired a new stake in Aprea Therapeutics, Inc. (NASDAQ:APRE) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 137,174 shares of the company’s stock, valued at approximately $558,000. Aprea Therapeutics accounts for approximately 0.5% of Stonepine Capital Management LLC’s holdings, making the stock its 21st biggest holding. Stonepine Capital Management LLC owned about 2.53% of Aprea Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 34.19% of the company’s stock.

Aprea Therapeutics Stock Down 1.1 %

NASDAQ:APRE traded down $0.04 during trading hours on Thursday, reaching $3.63. 2,389 shares of the company’s stock were exchanged, compared to its average volume of 42,959. Aprea Therapeutics has a 1-year low of $2.15 and a 1-year high of $8.85. The firm has a market capitalization of $19.71 million, a price-to-earnings ratio of -1.29 and a beta of 0.75. The company has a 50-day moving average of $3.35 and a 200 day moving average of $3.46.

Aprea Therapeutics (NASDAQ:APRE) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.11. The firm had revenue of $0.35 million for the quarter, compared to analyst estimates of $0.45 million. Aprea Therapeutics had a negative return on equity of 57.86% and a negative net margin of 1,029.50%. Research analysts forecast that Aprea Therapeutics will post -2.55 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Aprea Therapeutics in a report on Wednesday.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.